MONALEESA-3 study in HR+/HER2- advanced breast cancer

MONALEESA-3 study in HR+/HER2- advanced breast cancer

obr

1 year
107 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer.
Up Next Autoplay